PharmaPre-market
Strides Pharma shares rise 13% on strong Q2 results
pre-market1 source ↓written by the desknot a recommendation
- following its Q2
- 13%
- ₹131.5 cr
- Revenue increased
- 4.6%
- ₹1,221 cr
- while EBITDA rose
- 25.4%
Shares of Strides Pharma surged 13% following its Q2 results, with net profit up 82% to ₹131.5 cr. Revenue increased 4.6% to ₹1,221 cr, while EBITDA rose 25.4% to ₹232 cr. The EBITDA margin expanded to 19% from 15.8%, indicating strong operational performance. This momentum may enhance investor sentiment.
Not investment advice. For informational purposes only.